Drug Trial Radar · NCT05744427
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
725
Planned (sponsor's estimate)
Start
Mar 15, 2023
Primary completion
Jul 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open, multicenter study of phase I/II in Chinese subjects with unresectable locally advanced/metastatic solid tumors. It is divided into the dose escalation period and the cohort expansion period. A total of 8 dose groups (Q3W on the first day of intravenous administration) were designed in the dose escalation period. The initial dose was 1.0mg/kg administered Q3W, with a DLT observation period of 21 days. In the dose expansion phase, 7 cohorts were established.
Conditions
- Advanced Solid Tumor
Interventions
JSKN003Drug
JSKN003 should be administered intravenously on the first day of each 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT (dose escalation period) in phase 1.Time frame: Up to 12 months
- Maximum Tolerated Dose (MTD) or RP2D in phase 1。Time frame: Up to 12 months
- Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events in phase 1.Time frame: Throughout the duration of the study, approximately 2 years
- Objective Response Rate (ORR) in phase 2Time frame: Throughout the duration of the study, approximately 2 years
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Beijing Friendship Hospital
Beijing, China
Beijing Luhe Hospital
Beijing, China
Hunan Cancer Hospital
Changsha, China
Fujian Cancer Hospital
Fuzhou, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
Sun Yat-sen University Cancer Prevention Center
Guangzhou, China
Affiliated Cancer Hospital of Harbin Medical University
Ha’erbin, China
Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Anhui Provincal Hospital
Hefei, China
Shandong Cancer Hospital
Jinan, China
Linyi City Cancer Hospital
Linyi, China
Linyi City People's Hospital
Linyi, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Gulou Hospital Affiliated to Nanjing University School of Medicine
Nanjing, China
Jiangsu Cancer Hospital
Nanjing, China
Jiangsu Provincial People's Hospital
Nanjing, China
The First Affiliated Hospital of Nanjing Medical University/Jiangsu Provincial People's Hospital
Nanjing, China
Affiliated Cancer Hospital of Guangxi Medical University
Nanning, China
Nantong Cancer Hospital
Nantong, China
Affiliated Hospital of Qingdao University
Qingdao, China
Affiliated Cancer Hospital of Fudan University
Shanghai, China
Changhai Hospital
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanghai East Hospital
Shanghai, China
The Second Affiliated Hospital of Soochow University
Suzhou, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Zhongnan Hospital of Wuhan University
Wuhan, China
Xuzhou Central Hospital
Xuzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.